Market Size (2015)
2015
$2.16B
Vertical: HealthcareBase Year: 201712 Sections
Market Size (2015)
2015
$2.16B
Projected (2023)
2023
$2.92B
CAGR (2015–2023)
3.8%
3.8%Key Players
108+
Vocal cord paralysis is caused by the disruption of nerve impulses to the muscles of the larynx or voice box. Vocal cord paralysis may be caused by injury to the head, neck, or chest; lung or thyroid cancer; tumors of the neck or chest; or infection. The nerves controlling the vocal cords are long and can be vulnerable to injury in parts of the body, not usually associated with the vocal cords. The factors that are anticipated to propel the growth of the global vocal cord paralysis treatment market include the growing occurrences of the causes of vocal cord paralysis, technological advancements in the medical field, and rising healthcare expenditure. However, the high cost associated with the treatments may hinder the growth of the market during the forecast period.
The global vocal cord paralysis treatment market is expected to reach USD 2920.2 million by 2023 from USD 2334.7 million in 2017 and is expected to register a CAGR of 3.8% during the forecast period from 2018 to 2023. In 2017, the market was led by the Americas with 35.4% share, followed by Europe and Asia-Pacific with shares of 32.4% and 23.5%, respectively.
The global vocal cord paralysis treatment market has been segmented based on type, treatment, and region.
On the basis of type, Unilateral accounted for the largest market share of 89.3% in 2017, with a market value of USD 2145.1 million, which is projected to register a CAGR of 3.6% during the forecast period.
Based on treatment, voice therapy accounted for the largest market share of 62.8% in 2017, with a market value of USD 1508.7 million, which is projected to register a CAGR of 3.4%.
The Vocal Cord Paralysis Treatment Market market is projected to grow at a CAGR of 3.8% from 2015 to 2023.
Historical performance and future projections (2020–2030, USD Billion)
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansMarket Size (USD Mn)
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansVocal cord paralysis is a condition caused when the nerves going to the vocal cord are damaged leading to the interruption of nerve impulses in the larynx or the voice box. In other terms, vocal cord paralysis occurs when one or both the vocal cords do not function properly.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansThis report applies a rigorous multi-stage research process combining primary interviews, secondary data sources, and bottom-up market modelling to ensure accuracy and completeness across all segments and geographies.
Base Year
2017
Historical Period
2015 – 2017
Forecast Period
2017 – 2023
Primary Interviews
150+
Historical data (2015–2017) and forecast period (2017–2023)
Our research process spans primary interviews with industry stakeholders combined with comprehensive secondary data analysis, validated through triangulation across multiple independent sources.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansBargaining Power of Suppliers
Bargaining power of suppliers in the vocal cord paralysis treatment market is medium. Currently, the market consists of a limited number of players. However, few existing key companies capture significant share in the market and have the capability of fluctuating the costs of the products used for diagnosis and treatment of vocal cord disease. The overall bargaining power of suppliers in the global vocal cord paralysis treatment market is medium.
Bargaining Power of Buyers
The bargaining power of buyers is medium in the global vocal cord paralysis treatment market. The presence of buyers in the market is rising, as the prevalence of vocal cord paralysis, and related causative factors are growing steadily. In addition, buyers are price sensitive, which moderately affects their bargaining power in the market. The market is characterized by a low availability of substitute product which reduces the buying power in the industry.
Threat of New Entrants
The threat of new entrants in the global vocal cord paralysis treatment market is medium. Any company trying to enter the market is required to accept the mandatory regulatory standards issued by government authorities. The market is also characterized by a high degree of brand loyalty where establishing a brand name is difficult for newcomers. Furthermore, the cost involved in research and development (R&D) is comparatively high which does not comfort the new entrants to enter the market easily.
Threat of Substitutes
The threat of substitutes in the global vocal cord paralysis treatment market is low to medium. There are very less substitutes available in the market, and buyer propensity to substitute is low. So, quality and trust issue and excellent service provided by the existing players restrict the threat by the substitutes.
Intense Rivalry
The degree of competition in the global vocal cord paralysis treatment market is low to medium. The moderate degree of product differentiation among existing players increases the intensity of rivalry in the market. Companies involved in vocal cord paralysis treatment market are trying to introduce more advanced diagnostic equipment, for differentiating their product from their rivals. Additionally, very few companies are focused on the development of treatment options for vocal cord paralysis which further adds to the fewer chances of rivalry in the market.
Market estimates by geography (2023)
InsightEurope leads with $958.15M by 2023, while Asia Pacific is projected to grow fastest at a 4.2% CAGR.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription Plans| REGION | 2015 | 2017 | 2023 | CAGR | SHARE |
|---|---|---|---|---|---|
| Middle East and Africa | $188.65M | $220.63M | $257.15M | 3.9% | 9% |
| North America | $580.93M | $671.62M | $772.92M | 3.6% | 26% |
| Asia Pacific | $503.61M | $593.61M | $697.42M | 4.2% | 24% |
| Europe | $697.38M | $818.79M | $958.15M | 4.1% | 33% |
| South America | $192.18M | $210.89M | $234.61M | 2.5% | 8% |
| Total | $2.16B | $2.52B | $2.92B | 3.8% | 100% |
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansTotal Market Size
$2.97B
| APPLICATION | REVENUE ($B) | GROWTH RATE | MARKET PENETRATION |
|---|---|---|---|
| Unilateral | $2.65B | 3.8% | 67% |
| Bilateral | $323.11M | 3.8% | 60% |
* Revenue projections based on 2025 estimates. Growth rates represent CAGR 2024–2030. Market penetration indicates current adoption rate within addressable market segments.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSee plans for professionals or small and medium businesses.

Analytical insights on Vocal Cord Paralysis Treatment Market covering market dynamics, competitive landscape, and strategic outlook.
The Vocal Cord Paralysis Treatment Market market is projected to reach $2.92B by 2023, growing at 3.8% CAGR. The Unilateral segment holds the largest share.
Vocal cord paralysis is the common congenital defect of the voice box or larynx. Vocal cord paralysis or vocal fold paralysis is an inability of one or both vocal cords to move properly. It results from the abnormal nerve input to laryngeal muscles. Factors such as technological advancements, increasing prevalence of causing factors of voice cord paralysis, and growing healthcare expenditure are expected to drive the growth of the market during the forecast period. However, high cost associated with the treatment of vocal cord paralysis may restrain the market growth during the forecast period.
The etiological factors causing vocal cord paralysis include accidental brain trauma, surgeries, and neoplasm, among others. Surgeries that carry a risk of vocal cord paralysis include surgeries to the thyroid or parathyroid glands, esophagus, neck, and chest. The rising prevalence of brain and neck injuries increase the chances of damage to the vocal cord. According to the Centers for Disease Control and Prevention (CDC) in 2014, approximately 2.5 million people sustain a traumatic brain injury annually in the US. Moreover, the growing occurrences of head, neck, and larynx cancers are expected to significantly contribute to the growth of the market. According to the American Cancer Society, the estimated number of new cancer cases involving larynx was 13,360 in the US for the year 2017. As per the Australian Institute of Health and Welfare, an estimated 4,956 new cases of head and neck cancer were diagnosed in 2017 in Australia. According to an article published in the National Center for Biotechnology Information (NCBI) in 2015, the average rate of temporary vocal cord paralysis was 9.8%, whereas the average rate of permanent vocal cord paralysis was 2.3%.
The growing availability of funding and reimbursement for certain vocal cord paralysis treatments in developed countries such as the US can be a huge opportunity for the market during the assessment period. Medicare and some private insurers provide reimbursement to hospitals for patients undergoing tracheostomy procedures. Moreover, according to the data mentioned in The American Laryngological Rhinological and Otological Society, Inc. in 2015, about 72% reimbursement for endoscopy suite (ES) hospital injection laryngoplasty and 31% for operating room (OR) injection laryngoplasty are available in the US.
The increasing occurrences of vocal cord dysfunction have led to the development of various treatment options; however, the costs of these treatments are generally high. The high cost associated with the treatment of vocal cord paralysis is hampering the growth of the market. The average cost of injection laryngoplasty is USD 698.65 per patient. In one recent report by the National Institutes of Health, the average hospital charges were about USD 123,000 with a percutaneous tracheostomy and about USD 156,000 with an open tracheostomy. In addition to this, the cost of vocal fold medialization was about USD 2,200 in 2017.
Near-term growth will likely concentrate in modular bioreactor lines and closed-system media workflows that shorten validation cycles while preserving batch traceability.
Partnerships between CDMOs and instrumentation vendors should accelerate standard datasets for comparability across sites, improving forecasting models used in capacity planning.
Longer horizon, organoid and microphysiological adoption may reshape segment mix; teams that invest early in assay interoperability and cloud QC hooks are better positioned to capture upside without fragmenting their analytics stack.
Profiles of 108 companies operating in the Vocal Cord Paralysis Treatment Market market, including revenue, employee count, and market positioning where available.
Showing 108 of 108 companies
Olympus Corporation
Company Headquarters: Japan Founded: 1919 Workforce: 46,500 Company Working: Olympus Corporation is a Japanese multinational corporation that specializes in manufacturing and selling optical and reprography products, as well as medical and surgical equipment. The company was founded in 1919 and is headquartered in Tokyo, Japan. Olympus Corporation is organized into four main business segments: Medical, Scientific Solutions, Imaging, and Financial. The Medical segment is the largest and most important business segment of the company, accounting for approximately two-thirds of the company's total revenue. The Medical segment includes endoscopy and surgical products, as well as clinical and research microscopes which includes Biopsy devices. Within the Medical segment, Olympus Corporation offers a range of products for minimally invasive surgical procedures, including endoscopes and endotherapy devices. One of the key products offered by Olympus Corporation is its biopsy device, which is used to collect tissue samples from various parts of the body for diagnostic purposes. Olympus Corporation's biopsy device is designed to be used with endoscopes and comes in a range of sizes and shapes to suit different clinical needs. The company has a global presence with operations in various regions around the world. The company's headquarters is located in Tokyo, Japan, and it has several subsidiaries and offices in different countries.
FUJIFILM Holdings Corporation
Company Headquarter: Minato, Tokyo, Japan Founded: 1934 Workforce: 77,739 Employees (2017) Company Working: FUJIFILM Holdings Corporation company is engaged in developing, manufacturing, and marketing the imaging, information, and document solutions. Its product portfolio includes color films, digital cameras, photofinishing products, and equipment. The company manufactures medical equipment, optical devices, and provides services for office copy machines, printers, and related equipment.
Therapy Solutions Inc
Company Headquarter: Narberth, Pennsylvania, US Company Working: The company provides comprehensive therapeutic services for a wide range of developmental delays, speech-language therapy, physical therapy, and occupational therapy along with educational and psychological services. Moreover, the company also offers private office-based speech therapy services.
LifeCell Corporation
LifeCell Corporation is a regenerative medicine company engaged in developing and marketing tissue repair products for reconstructive, urogynecologic, and orthopedic surgical procedures. As of February 1, 2017, the company operated as a subsidiary of Allergan plc. As the company is the subsidiary of Allergan Plc, hence, financials of Allergen Plc are mentioned.
Smiths Group
Company Headquarter: London, UK Founded: 1851 Workforce: 7700 Employees (2017) Company Working: Smiths Group plc designs, manufactures, and sells a broad range of products and services globally. The medical division of the company provides specialty medical devices and consumables, including infusion systems, vascular access, temperature management equipment, and specialty devices in areas of diagnostics and emergency patient transport. The company has its presence in over 120 countries.
Teleflex Incorporated
Company Headquarter: Wayne, Pennsylvania, US Founded: 1981 Workforce: 14,000+ Employees (2017) Company Working: Teleflex Incorporated is engaged in designing, developing, manufacturing, and supplying single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications globally. Its vascular access product portfolio comprises arrow branded catheters and related devices, including catheter positioning systems for use in the administration of intravenous medications and other therapies, and devices for treating coronary and peripheral vascular disease. Moreover, the company serves hospitals and healthcare providers, medical device manufacturers, and home care markets.
Powering the world's best teams.
From next-gen startups to established enterprises.
Trusted by forward-thinking businesses
for data-driven intelligence
Vocal Cord Paralysis Treatment Market